Startups
Bioxodes
Gosselies, Belgium
Bioxodes SA is a Belgian clinical-stage biotechnology company developing therapies for thrombotic and inflammatory diseases, with a primary focus on intracerebral hemorrhage and secondary brain injury after stroke. Its investigational lead BIOX-101, formerly Ir-CPI, is a recombinant version of a protein derived from tick saliva designed to inhibit activated coagulation factors XI and XII and neutrophil-associated inflammation. The company reports Phase 2a BIRCH clinical research and preparation for a larger Phase 2b study planned for 2027; potential ischemic-stroke indications remain development plans. EMA granted orphan designation EU/3/25/3037 on March 25, 2025 for nontraumatic spontaneous intracerebral haemorrhage. This designation is distinct from marketing authorization, and no approved therapy or established efficacy is asserted. Current published leadership includes CEO and managing director Marc Dechamps, chairman Philippe Monteyne and CMO Hans Warrinnier, alongside a clinical advisory board. Belgian government enterprise BE0825.151.779 has been legally active since April 20, 2010 and adopted its current SA form in June 2013; the company describes its biotech launch as founded in 2013. Its November 2023 EUR12M financing package included EUR8.6M capital and EUR3.4M non-dilutive Walloon support. It separately announced EUR2.7M and EUR5.5M Series A extensions in February and December 2025, but the stated cumulative totals are inconsistent and the overlap is unresolved; no unsupported combined cash total is asserted. Its proposed EUR80M Series B is a fundraising target. Native portfolio logos are recorded separately from named participation in specific cash rounds.
Founded 2010
Team
 Ashkan ShoamaneshClinical Advisory Board Member |
 Cedric HermansClinical Advisory Board Member |
 Charlotte CorbisierClinical Operations Lead |
 Charlotte CordonnierClinical Advisory Board Member |
 Cindy HespelRegulatory Affairs Lead |
 David SeiffgeClinical Advisory Board Member |
 Didier Le NormandChief Financial Officer, Consultant |
 Else Charlotte SandsetClinical Advisory Board Member |
 François FontaineNon-Executive Director |
 Hans WarrinnierChief Medical Officer |
 Magdy SelimClinical Advisory Board Member |
 Marc DechampsManaging Director · Chief Executive Officer |
 Matthias EndresClinical Advisory Board Member |
 Neshika SamarasekeraClinical Advisory Board Member |
 Philippe MonteyneChairman |
 Pierre DetrixheNon-Executive Director |
 Robin LemmensClinical Advisory Board Member |
 Rustam Al-Shahi SalmanClinical Advisory Board Member |
 Sandrine DerochetteQuality Assurance & Project Manager |
 Stéphanie DemoulinIP Manager & Medical Writer |
 Thérèse CroughsNon-Executive Director |
 Tomas ComblainHead of Finance |
 Valérie PireauxPreclinical Operations Manager & Clinical Data Reviewer |